News | June 28, 2022
PHARMAP 2022 concludes with productive networking of pharma leaders
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
